Astellas Pharma Inc (4503.T)
|Market Cap (Mil.):||¥2,211,709.00|
|Shares Outstanding (Mil.):||456.96|
(Updates Kabel Deutschland; Adds Siemens, PPR, Dell, Astellas Pharma, Nokia, Lekoil, Nordea, Chevron)
NEW YORK - Japanese drugmaker Astellas Pharma Inc is looking to sell its dermatology portfolio, which could be worth between $500 million and $1 billion, according to three people familiar with the situation.
- Amgen Inc, the world's largest biotechnology company, said it entered into a long-term collaboration with Astellas Pharma Inc and will form a joint venture with the Japanese drugmaker to provide new medicines in Japan.
* Sees first commercial launch of new drug in Japan in 2016
ZURICH, May 28 - Swiss biotech group Basilea has won coveted orphan drug status from U.S. health authorities for antifungal treatment isavuconazole, the company said on Tuesday.
- Aveo Pharmaceuticals Inc said it was informed by its partner Astellas Pharma Inc that the Japanese company would not be seeking marketing approval for their experimental kidney cancer drug in Europe.
LONDON - European regulators have recommended approval of two new cancer drugs, called Erivedge and Xtandi, from Roche and Astellas, underscoring a recent pick-up in novel treatments for the disease.
LONDON, April 26 - European regulators have recommended approval of two new cancer drugs, called Erivedge and Xtandi, from Roche and Astellas, underscoring a recent pick-up in novel treatments for the disease.
LONDON, April 26 - European regulators have recommended approval of two new cancer drugs, called Erivedge and Xtandi, from Roche and Astellas.
LONDON - Japan's Astellas Pharma and Britain's GlaxoSmithKline are competing to develop a new kind of medicine that boosts production of red blood cells by making the body think it is at high altitude.
Earnings vs. Estimates
Analyst Research Reports
Provider: Thomson Reuters Stock Report
Astellas Pharma Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Wright Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.